UF awarded $11.9 million for prostate cancer research comparing proton and X-ray therapies

Dr. Nancy Mendenhall

A University of Florida research team has been approved for a five-year, $11.9 million award to directly compare the potential benefits and harms of proton therapy to standard radiation therapy when treating prostate cancer.

Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, leads the team that received funding from the Patient-Centered Outcomes Research Institute, or PCORI, for a large-scale pragmatic clinical study on prostate cancer — the most common non-skin cancer afflicting men in the United States, according to the American Cancer Society.

Mendenhall, also a professor and associate chair in the department of radiation oncology at UF, and Ronald Chen, M.D., an associate professor in the department of radiation oncology at the University of North Carolina at Chapel Hill, are the study’s principal investigators.

“This is a critically important study that will compare outcomes between proton and conventional radiation in cohorts of 3,000 men with prostate cancer,” said Mendenhall. “It will determine whether there are differences in disease control, toxicity and quality of life in survivors — providing much-needed answers to patients, families, medical teams, hospitals, insurers and policymakers.”

The study will compare 1,500 patients treated with proton therapy with 1,500 patients treated with standard radiation therapy from a total of 42 treatment centers across the United States. The study will collect information on patient-reported quality of life, physician-reported and patient-reported side effects, and prostate cancer recurrence. Some participants receiving proton therapy will also be randomly assigned to receive eight weeks of treatment at a lower intensity or four weeks at a higher intensity, to determine which regimen has a greater impact on cure rates and side effects.

“This large, multi-institutional PCORI-funded study led by Dr. Mendenhall represents a concrete opportunity to move the field of radiation oncology toward the best approaches to reducing suffering and curing this oftentimes devastating disease,” said Paul Okunieff, M.D., a professor and chair of the department of radiation oncology at UF.

Mendenhall’s team collaborated with several stakeholders to design this study, including patients, caregivers, prostate cancer advocacy groups, insurers and minority engagement groups — because, according to the American Cancer Society, the disease occurs more often in African-American men and in Caribbean men of African ancestry than in men of other races.

Mendenhall’s study was selected for funding through PCORI’s Pragmatic Clinical Studies Initiative, an effort to produce results that are broadly applicable to a diverse range of patients and care situations and can be more quickly taken up in routine clinical practice. It was one of 14 studies selected through a highly competitive review process in which patients, caregivers and other stakeholders joined scientists to evaluate the proposals.

“Dr. Mendenhall is a visionary clinician and research scientist who’s a driving force in this country in advocating for less-toxic radiation therapy,” said Jonathan Licht, M.D., director of the UF Health Cancer Center. “This is the type of leading-edge, pragmatic clinical study that we at the University of Florida want to be known for.”

PCORI is an independent, nonprofit organization authorized by Congress in 2010. Its mission is to fund research that provides patients, their caregivers and clinicians with the evidence-based information needed to make better-informed health care decisions. The UF award has been approved pending completion of a business and programmatic review by PCORI staff and issuance of a formal award contract.

About This Newsletter

The Precision Newsletter is an electronic-only publication that is distributed by email. Each issue is sent monthly to patients, alumni patients and friends of the University of Florida Health Proton Therapy Institute. As the official newsletter of the Institute, the content is compiled and prepared by our communications representative and approved by the editor Stuart Klein, executive director of UF Health Proton Therapy Institute. Special bulletin newsletters may occasionally be prepared when timely topics and new developments in proton therapy occur. If you would like to send a Letter to the Editor, please click here.

 

Keep In Touch

It is easy to stay in touch with us online at floridaproton.org . Look at the top right corner of the homepage for Facebook , Twitter and YouTube icons, click and join us in the social media conversation. Also on the right side of the homepage there is a button for VTOC Patient Portal . Click here to open your secure account, view your records, complete clinical trial questionnaires and communicate with your nurse case manager.

 

Knowing how you are feeling during and after treatment is essential to providing you the best care possible and contributes to the care of future patients.